Postpartum Low-Dose Aspirin and Preeclampsia

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Columbia University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Singleton or Multiple gestation

• Maternal age >= 18 years

• 20 0/7 weeks gestation or greater

• Severe Preeclampsia diagnosed prior to delivery

Exclusion Criteria:

• Aspirin use postpartum for other medical indication

• Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)

• Aspirin use within 7 days of planned initial FMD testing postpartum

• Hypersensitivity or allergy to Aspirin or other salicylates

• Hypersensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) - exception if taking LDA in pregnancy

• Nasal polyps

• Gastric or Duodenal ulcers, history of GI bleeding

• Severe hepatic dysfunction

• Bleeding disorders and diathesis

• Breastfeeding a newborn with low platelets (NAIT)